Loading clinical trials...

Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome | Clinical Trials | Clareo Health

COMPLETEDNA

Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome

NCT02092402•Örebro University, Sweden

Summary

The purpose of this study is to investigate the effect of fecal microbiota transplantation (FMT) on the symptoms of irritable bowel syndrome (IBS) patients.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Signed informed consent
•2. Fulfilled Rome III diagnostic criteria for IBS, and frequency of IBS pain or discomfort for at least 2 days a week in the last 12 weeks
•3. Age: 18-65 years
•1. Signed informed consent
•2. High-butyrate producing microbiota in fecal samples
•3. Age: 18-65 years

Exclusion Criteria

•1. High proportion of butyrate-producing microbiota in fecal samples
•2. Known organic gastrointestinal disease (e.g. IBD)
•3. Previous complicated gastrointestinal surgery
•4. Non-gastrointestinal malignancy
•5. Dementia, severe depression, major psychiatric disorder, or other incapacity for adequate cooperation
•6. Females who are pregnant or breast-feeding
•7. Severe endometriosis
•8. Antimicrobial treatment 4 weeks prior to first screening visit
•9. Antimicrobial prophylaxis (eg. acne, urinary tract infection)
•10. Regular consumption of probiotic products 4 weeks prior to randomization
+24 more criteria

Locations (1)

University Hospital Örebro

Örebro, Sweden

Key Dates

Start Date

September 1, 2013

Primary Completion Date

November 1, 2016

Completion Date

June 1, 2019

Last Updated

August 28, 2019

Enrollment

ACTUAL participants

Conditions

Irritable Bowel Syndrome (IBS)

Interventions

Fecal transplantation

OTHER

Safety and Efficacy of Lyophilized Faecal Microbiota Transplantation Via Capsules in Treatment of Irritable Bowel Syndrome

NCT07481422

Irritable Bowel Syndrome (IBS)

View study

ENROLLING_BY_INVITATION

Enabling Microbiomics- Driven Personalized Nutrition

NCT06657001

Inflammatory Bowel Disease (IBD)Irritable Bowel Syndrome (IBS)+8 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 28, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome

Inclusion Criteria

Exclusion Criteria

Safety and Efficacy of Lyophilized Faecal Microbiota Transplantation Via Capsules in Treatment of Irritable Bowel Syndrome

Enabling Microbiomics- Driven Personalized Nutrition

Investigating the Gut Microbiome and Symptomology in IBS

Effect of HMOs as Nutritional Support for Normal Bowel Movements in IBS Patients

Physical Activity in IBS - a Long Term Follow up